CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GYASI, H. K.
Right arrow Articles by NAGUIB, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by GYASI, H. K.
Right arrow Articles by NAGUIB, M.

Canadian Journal of Anesthesia, Vol 32, 161-164, Copyright © 1985 by Canadian Anesthesiologists' Society

Atracurium and Severe Hepatic Disease: A Case Report

HENRY K. GYASI MB CHB FFARCSI1 and MOHAMED NAGUIB MB BCH MSC1

1 Department of Anaesthesiology, King Faisal University, King Fahd Hospital, P.O. Box 2208, Al-Khobar 31952, Saudi Arabia

Address correspondence to: Dr. H.K. Gyasi.

Atracurium is a new non-depolarising neuromuscular blocking agent, metabolized through Hofmann elimination. A case is presented in which a 45-year-old patient with severe liver disease showed a decreased response to atracurium. The possible causes of resistance to atracurium are discussed. We conclude that atracurium may be used in patients with severe hepatic disease.

Key Words: NEUROMUSCULAR RELAX ANTS: atracurium, succinylcholine • ENZYMES: plasma cholinesterase • LIVER: function






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by the Canadian Anesthesiologists' Society.